



## **LASA SUPERGENERICS LIMITED**

**CORPORATE OFFICE:** B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.  
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/20-21/39

Thursday, December 16, 2021

<b>To,</b> <b>Corporate Services Department</b> <b>BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street,</b> <b>Mumbai – 400 001.</b> <b>BSE CODE –540702</b>	<b>To,</b> <b>Corporate Services Department</b> <b>National Stock Exchange of India Limited</b> <b>“Exchange Plaza”, Plot No. C/1,</b> <b>G Block Bandra-Kurla Complex,</b> <b>Bandra (E), Mumbai – 400 051.</b> <b>NSE CODE: LASA</b>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

**Subject: Media Release**

Attached is the copy of Media Release titled **Hon’ble High Court of Judicature at Bombay ordered “Closure dated 06.10.2021 of MPCB shall not be acted on and it shall be treated as show cause Notice”**

You are requested to take the same on your record.

**Yours Sincerely**  
**FOR LASA SUPERGENERICS LIMITED**

**Omkar Herlekar**  
**Managing Director**



**Lasa Supergenerics Limited**

CIN: L24233MH2016PLC274202

**Media Release**

**Hon'ble High Court of Judicature at Bombay ordered "Closure dated 06.10.2021 of MPCB shall not be acted on and it shall be treated as show cause Notice"**

**Mumbai, 15th December 2021:** Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain announced, that it has received order from Hon'ble High Court, Bombay setting aside disconnection of electricity and water supply on notice of MPCB and also closure dated 06.10.2021 of MPCB shall not be acted on and it shall be treated as show cause notice.

With this order company can restart its mother unit situated at Chiplun, Additionally Hon'ble High Court has also ordered MPCB for re-inspection in the matter of other units and restarts those units on satisfaction which was one of the reliefs we sought.

Commenting on the recent development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

*It is heartening to comment on the process of restarting our mother unit which is in advanced stage. We are fortunate enough to have such a judiciary system which actively gets into a situation and ensures that rule of Law is Supreme, justice is impartial to all.*

*Coming on business, yes we have lost few days in forced closure however, our order books are full for next few months and we are targeting to meet the time gap of production loss in every possible means with full enthusiasm.*

*At this juncture once again I would like to thank our management team, our suppliers who came forward to support in this testing times so that we can restart our operations at the earliest.*

*Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."*

**About Lasa Supergenerics Limited ([www.lasalabs.com/](http://www.lasalabs.com/); BSE: 540702; NSE: LASA)**

Founded in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of



## Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

4,300 MT. The Company has over 25% of APIs exported to countries like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: [www.lasalabs.com](http://www.lasalabs.com)

For any Investor Relations query, please contact:

**Mr. Hitesh Wadhvani**

**Lasa Supergenerics Limited**

Email: [hitesh@lasalabs.com](mailto:hitesh@lasalabs.com)

**Note:** *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*